Skip to content
New: 100+ more US companies, including the big banks, plus insider trades from SEC filings

Compare · Health Care

Intuitive Surgical vs. Stryker: how they make money

The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

How they differ

In FY2025, Stryker's revenue of $25.1B was about 2.5 times Intuitive Surgical's $10.1B (Cityfort calculation: one divided by the other).

Intuitive Surgical's largest segment is Instruments and accessories, 59.8% of revenue in FY2025; Stryker's largest segment is MedSurg and Neurotechnology, 54.5% of revenue in FY2025.

United States brought in 68.0% of Intuitive Surgical's revenue in FY2025; United States brought in 75.7% of Stryker's revenue in FY2025.

Intuitive Surgical's largest payer group is U.S. hospitals, 68.0% of revenue (FY2025); Stryker's largest payer group is Hospitals and doctors in the US, 75.7% of revenue (FY2025).

Neither page lists the other among its competitors.

Sources: Intuitive Surgical S1, S3 · Stryker S1, S15

Each company in 5 points

Intuitive Surgical

  1. 1 · What it sells

    Intuitive Surgical sells da Vinci and Ion surgical robots and the instruments used in each operation: instruments and accessories brought in $6.02 billion of FY2025 revenue of $10.06 billion, systems $2.47 billion and services $1.57 billion.

    Sources and detail on the Intuitive Surgical page
  2. 2 · Who pays it

    Hospitals are Intuitive's customers, and U.S. customers made up 68% of FY2025 revenue while customers outside the U.S. made up 32%.

    Sources and detail on the Intuitive Surgical page
  3. 3 · What it keeps from $100

    Of every $100 that came in during FY2025, Intuitive kept $27.4 as net income, while operating profit, before $366 million of interest and other income and tax, was $29.3 per $100 of revenue.

    Sources and detail on the Intuitive Surgical page
  4. 4 · Where the operating profit comes from

    Intuitive reports one segment and no profit by product: FY2025 operating profit was $2.95 billion, after $3.42 billion of cost of revenue, $2.39 billion of selling and administration and $1.31 billion of research.

    Sources and detail on the Intuitive Surgical page
  5. 5 · The one thing to watch

    Worldwide da Vinci procedures grew about 18% in FY2025 and about 14% in Q3 FY2026, while the installed base reached 12,094 systems at Sep 30, 2026.

    Sources and detail on the Intuitive Surgical page

Stryker

  1. 1 · What it sells

    Stryker sells orthopedic implants, surgical and endoscopy equipment, patient care products and the Mako robot, with FY2025 net sales of $25.1 billion, 54.5% from MedSurg and Neurotechnology and 45.5% from Orthopaedics.

    Sources and detail on the Stryker page
  2. 2 · Who pays it

    Stryker reports no sales by type of payer and names no large customer; by selling location, customers in the US paid 75.7% of FY2025 net sales and customers outside the US 24.3%.

    Sources and detail on the Stryker page
  3. 3 · What it keeps from $100

    Of every $100 that came in during FY2025, Stryker kept $12.8 as net earnings after a 28.1% tax rate, and its operating income was $19.47 per $100 of sales.

    Sources and detail on the Stryker page
  4. 4 · Where the operating profit comes from

    In FY2025 Orthopaedics earned 50.6% of Stryker's segment operating income on 45.5% of net sales, and MedSurg and Neurotechnology 49.4% on 54.5%.

    Sources and detail on the Stryker page
  5. 5 · The one thing to watch

    Stryker lowered its FY2026 organic sales growth outlook to 6.5% to 7.0% on Oct 29, 2026, from 8.0% to 9.5% in January, and its Q3 FY2026 net earnings of $753 million included a $293 million goodwill impairment.

    Sources and detail on the Stryker page

Where each $100 went

Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.

Intuitive Surgical

Where $100 went · FY2025

Where $100 of Intuitive Surgical's money went in FY2025
Selling, general and administrative$22.8
Cost of revenue$32.8
Research and development$12.6
China joint venture partner's share$0.2
Income tax$4.2
Kept as net income$27.4
Total$100

Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (revenue of $10,064.7 million plus $365.9 million of interest and other income): each line = line ÷ $10,430.6 million × 100.

Stryker

Where $100 went · FY2025

Where $100 of Stryker's money went in FY2025
Selling, general and administrative$34.1
Making the products (cost of sales)$35.7
Research, development and engineering$6.4
Amortization and impairments$3.6
Interest$2.4
Income tax$5.0
Kept as net earnings$12.8
Total$100

Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (net sales of $25.1 billion plus $232 million of other income): each line = line ÷ $25.35 billion × 100.

Line items differ because each company groups its costs its own way in its filings. Only on Intuitive Surgical's receipt: Cost of revenue; Research and development; China joint venture partner's share; Kept as net income. Only on Stryker's receipt: Making the products (cost of sales); Research, development and engineering; Amortization and impairments; Interest; Kept as net earnings.

Sources: Intuitive Surgical S1 · Stryker S1

Revenue, net income and free cash flow

Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).

Revenue

Intuitive Surgical

Stryker

Both charts use the same scale. Each company's own fiscal years.
See the numbers
Revenue of Intuitive Surgical and Stryker by fiscal year, US$
Intuitive Surgical yearIntuitive Surgical revenueStryker yearStryker revenue
FY2021$5.7BFY2021$17.1B
FY2022$6.2BFY2022$18.4B
FY2023$7.1BFY2023$20.5B
FY2024$8.4BFY2024$22.6B
FY2025$10.1BFY2025$25.1B

Net income

Intuitive Surgical

Stryker

Both charts use the same scale. Each company's own fiscal years.
See the numbers
Net income of Intuitive Surgical and Stryker by fiscal year, US$
Intuitive Surgical yearIntuitive Surgical net incomeStryker yearStryker net income
FY2021$1.7BFY2021$2.0B
FY2022$1.3BFY2022$2.4B
FY2023$1.8BFY2023$3.2B
FY2024$2.3BFY2024$3.0B
FY2025$2.9BFY2025$3.2B

Free cash flow

Intuitive Surgical

Stryker

Both charts use the same scale. Each company's own fiscal years; free cash flow = cash from operations minus capital spending, as on each company's page.
See the numbers
Free cash flow of Intuitive Surgical and Stryker by fiscal year, US$
Intuitive Surgical yearIntuitive Surgical free cash flowStryker yearStryker free cash flow
FY2021$1.7BFY2021$2.7B
FY2022$958MFY2022$2.0B
FY2023$750MFY2023$3.1B
FY2024$1.3BFY2024$3.5B
FY2025$2.5BFY2025$4.3B

Sources: Intuitive Surgical S3, S1 · Stryker S1, S2

Growth and net margin, FY2021 to FY2025

Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.

Intuitive Surgical

Revenue, per year
+15.2%
Net income, per year
+13.8%

Stryker

Revenue, per year
+10.1%
Net income, per year
+13.0%

Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.

Net margin by year
Net margin (net income as a share of revenue) of Intuitive Surgical and Stryker by fiscal year, as on each page
YearIntuitive SurgicalStryker
FY202129.9%11.7%
FY202221.3%12.8%
FY202325.2%15.4%
FY202427.8%13.2%
FY202528.4%12.9%

Sources: Intuitive Surgical S3, S1 · Stryker S1, S2

Latest quarter, against the same quarter a year earlier

Each page's latest quarter as reported; the change is a Cityfort calculation.

Intuitive Surgical

Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025

Intuitive Surgical, Q3 FY2026 against Q3 FY2025
MeasureQ3 FY2026Q3 FY2025Change
Revenue$3.0B$2.5B+21.7%
Net income$523M$704M−25.8%

Stryker

Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025

Stryker, Q3 FY2026 against Q3 FY2025
MeasureQ3 FY2026Q3 FY2025Change
Revenue$6.5B$6.1B+7.6%
Net income$753M$859M−12.3%

Sources: Intuitive Surgical S11, S8, S10, S5 · Stryker S9, S10, S11, S12, S13, S3

Who pays each company

Intuitive Surgical

  • U.S. hospitals · 68.0% of revenueBuy or lease da Vinci and Ion systems, buy instruments for each procedure and pay for service. U.S. revenue was $6.82 billion in FY2025, including $4.20 billion of instruments and accessories.
  • Hospitals outside the U.S. · 32.0% of revenueServed directly in parts of Europe, Japan, Korea, India, Taiwan and Canada, through a joint venture in China and through distributors elsewhere. Revenue was $3.25 billion in FY2025.

Stryker

  • Hospitals and doctors in the US · 75.7% of revenueDoctors, hospitals and other healthcare facilities buying implants, equipment and disposables, reached mostly through Stryker's own sales teams.
  • Hospitals and doctors outside the US · 24.3% of revenueCustomers in Europe, the Middle East and Africa (12.7% of FY2025 net sales), Asia Pacific (8.6%) and Canada and Latin America (3.0%), served by Stryker subsidiaries and by distributors.

Sources: Intuitive Surgical S1 · Stryker S1

Revenue by segment

Intuitive Surgical

FY2025

Intuitive Surgical revenue by segment, FY2025
SegmentRevenueShare
Instruments and accessories$6.0B59.8%
Systems$2.5B24.6%
Services$1.6B15.6%

Stryker

FY2025

Stryker revenue by segment, FY2025
SegmentRevenueShare
MedSurg and Neurotechnology$13.7B54.5%
Orthopaedics$11.4B45.5%

Sources: Intuitive Surgical S1, S3 · Stryker S15

Where the revenue comes from

Revenue by region, as each company splits it, with the period.

Intuitive Surgical

FY2025

  • United States68.0%
  • Outside the United States32.0%

Stryker

FY2025

  • United States75.7%
  • Europe, Middle East and Africa12.7%
  • Asia Pacific8.6%
  • Canada and Latin America3.0%

Sources: Intuitive Surgical S1 · Stryker S1

Debt and cash

Intuitive Surgical

Debt
$0M
Cash and investments
$6.8B

On Sep 30, 2026.

At Sep 30, 2026, Intuitive had no borrowings and $6.80 billion of cash and investments, down from $9.03 billion at Dec 31, 2025.

Stryker

Debt
$14.9B
Cash and investments
$3.3B

On Sep 30, 2026.

Net debt was $11.7 billion at Sep 30, 2026, about 1.9 times FY2025 EBITDA of $6.1 billion (Cityfort calculation from the FY2025 10-K and the Q3 FY2026 10-Q).

Sources: Intuitive Surgical S5, S8, S1 · Stryker S3, S1, S29, S31

Who owns each company

Intuitive Surgical

  • One class of shares.
  • Officers and directors as a group: 0.6% of shares (as of Dec 31, 2025).
  • BlackRock, Inc.: 8.6% (as of Dec 31, 2025).
  • Vanguard Capital Management: 7.5% (as of Mar 31, 2026).

Stryker

  • One class of shares.
  • Officers and directors as a group: 4.6% of shares (as of Feb 28, 2026).
  • Vanguard Capital Management LLC: 6.7% (as of Apr 30, 2026).
  • BlackRock, Inc.: 6.5% (as of Jan 29, 2024).
  • John W. Brown: 5.2% (as of Feb 9, 2021).
  • 3 more holders on the Stryker page.

Sources: Intuitive Surgical S16, S5, S26, S24, S23 · Stryker S14, S3, S23

What protects each business

What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.

Intuitive Surgical

  • Installed base and recurring use

    11,106 da Vinci systems were installed at Dec 31, 2025, and about 3.15 million da Vinci procedures were done in FY2025, each using Intuitive's instruments.

  • Surgeon training and hospital workflow

    Surgeons operate from Intuitive's console and can train on its SimNow simulator. System sales generally include five years of service, and service contracts have generally been renewed, the 10-K says.

  • Research spending

    Research and development was $1.31 billion in FY2025, 13.0% of revenue, and da Vinci 5 placements reached 870 that year.

Stryker

  • Direct sales reach

    Stryker sells in about 61 countries through its own subsidiaries and distributors, and markets most products directly to doctors and hospitals.

  • Broad product range

    Nine of Stryker's ten product businesses had FY2025 net sales above $1 billion; the tenth, Spinal Implants, was sold in 2025. The largest, Medical, had $4.20 billion.

  • Steady gross profit

    Gross profit stayed between $62.8 and $64.1 per $100 of net sales in each year from FY2021 to FY2025.

  • Patents

    Stryker held about 5,600 US patents and about 9,000 patents outside the US at Dec 31, 2025.

Sources: Intuitive Surgical S1 · Stryker S1, S15

Where growth could come from

Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.

Intuitive Surgical

  • More procedures on installed robots · Working: on track against what the company saidda Vinci procedures +14% in Q3 FY2026
  • da Vinci 5 · Working: on track against what the company said315 of 546 placements in Q3 FY2026
  • Ion lung biopsies · Working: on track against what the company saidIon procedures +31% in Q3 FY2026
  • Procedures outside the U.S. · Working: on track against what the company saidAbout +23% in FY2025
  • Selling directly in southern Europe · New: recently announcedAbout $533 million, closed Mar 1, 2026

Stryker

  • Ortho Tech (Mako robot, power tools) · Working: on track against what the company said+15.8% in Q3 FY2026
  • Endoscopy · Working: on track against what the company said+13.9% in Q3 FY2026
  • Medical (patient care and emergency equipment) · Working: on track against what the company said+9.7% in Q3 FY2026
  • Vascular, including Inari Medical · Mixed: partly on track+8.0% in Q3 FY2026
  • Knees and hips · Mixed: partly on trackKnees +1.1%, hips −1.0%, Q3 FY2026

Sources: Intuitive Surgical S1, S8, S9, S10, S12, S5, S19 · Stryker S13, S15, S3

Dividends, buybacks, auditor and credit rating

Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.

Intuitive Surgical

  • Dividends per shareNo dividends on the page up to FY2025.
  • Buybacks
    • Dec 31, 2022: Bought back $2.61 billion of shares during FY2022. ($2.6B)
    • Dec 31, 2023: Bought 1.7 million shares for $416 million during FY2023. ($416M)
    • Dec 31, 2025: Bought 4.8 million shares for $2.30 billion during FY2025. ($2.3B)
    • Sep 30, 2026: Bought 11.0 million shares for $4.45 billion, an average of $405.51 a share, in the first nine months of 2026; 7.8 million of them in Q3 FY2026 for $2.94 billion. ($4.4B)
  • AuditorPricewaterhouseCoopers LLP, since 2014
  • Credit ratingNo public credit rating found.

Stryker

  • Dividends per shareFY2021: $2.59 (47.6% of profit) · FY2022: $2.84 (44.6% of profit) · FY2023: $3.05 (36.0% of profit) · FY2024: $3.24 (40.7% of profit) · FY2025: $3.40 (39.6% of profit)
  • Buybacks
    • Sep 30, 2026: Bought back 3 million shares for $1.0 billion in Q3 FY2026, the first repurchases since at least FY2021. The board added $3.0 billion to the authorization in October 2026, bringing it to $3.03 billion. ($1.0B)
  • AuditorErnst & Young LLP, since 1974
  • Credit ratingNo public credit rating found.

Sources: Intuitive Surgical S3, S1, S5 · Stryker S1, S2, S3, S13, S14

Risks only one page tracks

Risks whose type the other company's page does not list. Both pages track risks of these types: legal cases, regulation, demand. Every risk is on each company's page.

Intuitive Surgical

  • More robot makers entering the field (competition)The FY2025 10-K names 14 companies, including Medtronic and Johnson & Johnson, that have introduced robotic systems or said they plan to. It expects increasing competition in China and says rivals could bring pricing pressure.

Stryker

  • Cyber incident hit Q1 FY2026 (technology)A cybersecurity incident found on Mar 11, 2026 disrupted order processing, manufacturing and shipping. Stryker said it had a material impact on Q1 FY2026 results: net sales grew 2.6% and organic growth was 2.4%, against 7.7% to 11.0% in the seven other quarters from Q4 FY2024 to Q3 FY2026. The cost has not been disclosed. A Mar 20, 2026 letter from the outside investigators, Unit 42, filed with an 8-K on Mar 23, 2026, reported that all known signs of the intrusion had been addressed.
  • Peripheral Vascular impairment after the Inari deal (execution)Stryker paid $4.81 billion, net of cash acquired, for Inari Medical in February 2025. In Q3 FY2026 it booked a $293 million goodwill impairment on Peripheral Vascular, citing near-term operational and supply constraints and a longer expected path to growth.
  • Acquired assets are half of the balance sheet (execution)Goodwill and other intangible assets were $25.0 billion, 52.2% of total assets, at Dec 31, 2025. Impairments cut operating income by $977 million in FY2024 and $170 million in FY2025. The 10-K names acquisitions that do not deliver as a risk.
  • Pricing pressure from hospitals and governments (pricing)The 10-K names hospital cost-cutting, provider consolidation, government payers and China's volume-based procurement (bulk tendering) as sources of pressure on prices. US customers paid 75.7% of FY2025 net sales.

Sources: Intuitive Surgical S1 · Stryker S16, S17, S18, S11, S5, S32, S6, S7, S8, S9, S10, S12, S13, S1, S21, S3

Key facts

How does Intuitive Surgical make money compared with Stryker?
Intuitive Surgical's revenue by segment in FY2025: Instruments and accessories 59.8%, Systems 24.6%, Services 15.6%. Stryker's revenue by segment in FY2025: MedSurg and Neurotechnology 54.5%, Orthopaedics 45.5%.
Which is bigger by revenue, Intuitive Surgical or Stryker?
Intuitive Surgical reported $10.1B of revenue in FY2025, and Stryker reported $25.1B in FY2025.
How much net income did Intuitive Surgical and Stryker report?
Intuitive Surgical reported net income of $2.9B in FY2025, and Stryker reported $3.2B in FY2025.
How much of every $100 did Intuitive Surgical and Stryker keep as net income?
Intuitive Surgical kept $27.4 of every $100 that came in during FY2025, and Stryker kept $12.8 in FY2025 (Cityfort calculation from each company's annual report).
How much debt and cash do Intuitive Surgical and Stryker have?
Intuitive Surgical had $0M of debt and $6.8B of cash and investments on Sep 30, 2026. Stryker had $14.9B of debt and $3.3B of cash and investments on Sep 30, 2026.
When do Intuitive Surgical's and Stryker's fiscal years end?
Intuitive Surgical: Fiscal year ends on December 31. Stryker: December 31 (the fiscal year is the calendar year, so Q3 FY2026 is July to September 2026).

Sources: Intuitive Surgical S3, S1, S5, S8 · Stryker S1, S2, S15, S3, S29, S31

Built from each company's page. Intuitive Surgical updated Nov 6, 2026; Stryker updated Nov 6, 2026.

Sources

Intuitive Surgical

  1. S1Form 10-K, fiscal year 2025 (ended December 31, 2025), Intuitive Surgical, Inc. (SEC EDGAR), Feb 3, 2026
  2. S3Form 10-K, fiscal year 2023 (ended December 31, 2023), Intuitive Surgical, Inc. (SEC EDGAR), Jan 31, 2024
  3. S5Form 10-Q, third quarter 2026 (quarter ended September 30, 2026), Intuitive Surgical, Inc. (SEC EDGAR), Oct 21, 2026
  4. S8Third quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Oct 20, 2026
  5. S9Second quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Jul 16, 2026
  6. S10First quarter 2026 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Apr 21, 2026
  7. S11Fourth quarter and full year 2025 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Jan 22, 2026
  8. S12Third quarter 2025 earnings release (Form 8-K, Exhibit 99.1), Intuitive Surgical, Inc. (SEC EDGAR), Oct 21, 2025
  9. S16Definitive proxy statement for the 2026 annual meeting (DEF 14A), Intuitive Surgical, Inc. (SEC EDGAR), Mar 13, 2026
  10. S19Form 8-K, Exhibit 99.1: completion of the acquisition of the ab medica, Abex and Excelencia Robotica distribution businesses, Intuitive Surgical, Inc. (SEC EDGAR), Mar 2, 2026
  11. S23Schedule 13G/A (Amendment No. 10), The Vanguard Group, common stock (event date Mar 13, 2026), The Vanguard Group (SEC EDGAR), Mar 27, 2026
  12. S24Schedule 13G, Vanguard Capital Management, common stock (event date Mar 31, 2026), Vanguard Capital Management (SEC EDGAR), Apr 30, 2026
  13. S26EDGAR filing index, Intuitive Surgical, Inc. (CIK 0001035267), U.S. Securities and Exchange Commission, Nov 6, 2026

Stryker

  1. S1Form 10-K for fiscal 2025 (year ended Dec 31, 2025), Stryker Corporation (SEC EDGAR), Feb 11, 2026
  2. S2Form 10-K for fiscal 2023 (year ended Dec 31, 2023), Stryker Corporation (SEC EDGAR), Feb 14, 2024
  3. S3Form 10-Q for Q3 2026 (quarter ended Sep 30, 2026), Stryker Corporation (SEC EDGAR), Oct 30, 2026
  4. S5Form 10-Q for Q1 2026 (quarter ended Mar 31, 2026), Stryker Corporation (SEC EDGAR), May 11, 2026
  5. S6Q4 and full-year 2024 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jan 28, 2025
  6. S7Q1 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), May 1, 2025
  7. S8Q2 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jul 31, 2025
  8. S9Q3 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Oct 30, 2025
  9. S10Q4 and full-year 2025 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jan 29, 2026
  10. S11Q1 2026 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Apr 30, 2026
  11. S12Q2 2026 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Jul 30, 2026
  12. S13Q3 2026 earnings release (8-K Ex. 99.1), Stryker Corporation (SEC EDGAR), Oct 29, 2026
  13. S142026 proxy statement (DEF 14A), Stryker Corporation (SEC EDGAR), Mar 23, 2026
  14. S158-K (Item 8.01): recast of 2025 10-K items for the 2026 segment reorganization, Ex. 99.1, Stryker Corporation (SEC EDGAR), Jun 26, 2026
  15. S168-K (Item 8.01): cybersecurity incident identified Mar 11, 2026, Stryker Corporation (SEC EDGAR), Mar 11, 2026
  16. S178-K/A (Item 1.05): material cybersecurity incident, Stryker Corporation (SEC EDGAR), Apr 9, 2026
  17. S188-K (Item 7.01): cybersecurity incident update by the CISO, Stryker Corporation (SEC EDGAR), Mar 12, 2026
  18. S218-K (Item 2.01): completion of the Inari Medical acquisition, Stryker Corporation (SEC EDGAR), Feb 19, 2025
  19. S23Schedule 13G: Vanguard Capital Management LLC (event Mar 31, 2026), Vanguard Capital Management LLC (SEC EDGAR), Apr 30, 2026
  20. S298-K (Items 1.01, 2.03): $3.0 billion revolving credit agreement, Stryker Corporation (SEC EDGAR), Feb 27, 2025
  21. S31XBRL company facts: Stryker Corp (quarter-end debt split and cash), SEC (data.sec.gov), Nov 7, 2026
  22. S328-K (Item 7.01) Ex. 99.1: Unit 42 status letter on the cybersecurity incident, Stryker Corporation (SEC EDGAR), Mar 23, 2026

Disclaimer

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.

Read the positions policy
Read the full disclaimer

Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.

All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.